Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
65 hedge funds and large institutions have $122M invested in Clearside Biomedical in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
48% more call options, than puts
Call options by funds: $4.57M | Put options by funds: $3.09M
27% more capital invested
Capital invested by funds: $95.7M → $122M (+$25.9M)
25% more funds holding
Funds holding: 52 → 65 (+13)
0.01% less ownership
Funds ownership: 2.28% → 2.27% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.06M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.99M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$1.63M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.18M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$658K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
-$5.56M |
| 2 |
Two Sigma Investments
New York
|
-$1.52M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.04M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$509K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$181K |
CLSD Hedge Fund Activity: Q3 2021 in Review
65 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2021, worth a combined $122M — up 27% from $95.7M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CLSD positions and 6 closed out — a net gain of 14 holders — while 23 added to existing stakes and 10 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.06M. The largest seller was Carmignac Gestion, cutting an estimated $5.56M.
- 65 institutional investors held Clearside Biomedical (CLSD) as of Q3 2021, up from 52 in Q2 2021.
- Funds reported $122M of Clearside Biomedical stock for Q3 2021, up 27% quarter-over-quarter.
- 20 funds opened new Clearside Biomedical positions in Q3 2021 and 6 closed out, a net change of +14 holders.
- The largest Clearside Biomedical buyer in Q3 2021 was Morgan Stanley, an estimated $3.06M added.
- The largest Clearside Biomedical seller in Q3 2021 was Carmignac Gestion, an estimated $5.56M sold.
Based on aggregated 13F filings for Q3 2021.